J J Holst

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
    J J Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, Blegdamsvej 3, 2200 Copenhagen N, Denmark
    Diabetologia 48:612-5. 2005
  2. ncbi Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
    Philip J Larsen
    Rheoscience A S, The Panum Insitute, University of Copenhagen, Glerupvej 2, 2610 Rødovre, Denmark
    Regul Pept 128:97-107. 2005
  3. ncbi Delayed β-cell response and glucose intolerance in young women with Turner syndrome
    Britta E Hjerrild
    Department of Endocrinology and Internal Medicine and Medical Research Laboratories, Aarhus Sygehus NBG, Aarhus University Hospital, Denmark
    BMC Endocr Disord 11:6. 2011
  4. ncbi Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
    J J Holst
    Department of Medical Physiology, University of Copenhagen, Denmark
    Diabetes 47:1663-70. 1998
  5. ncbi Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
    J J Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen, Denmark
    Diabetologia 49:253-60. 2006
  6. ncbi On the physiology of GIP and GLP-1
    J J Holst
    Department of Medical Physiology, University of Copenhagen, 2200 Copenhagen N, Denmark
    Horm Metab Res 36:747-54. 2004
  7. ncbi The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism
    Jens Juul Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Diabetes 53:S197-204. 2004
  8. ncbi Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
    Jens Juul Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK 2200 Copenhagen N, Denmark
    Curr Opin Pharmacol 4:589-96. 2004
  9. ncbi Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
    Jens Juul Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 287:E199-206. 2004
  10. ncbi Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors
    Jens Juul Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK 2200 Copenhagen N, Denmark
    Adv Exp Med Biol 524:263-79. 2003

Detail Information

Publications115 found, 100 shown here

  1. ncbi Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
    J J Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, Blegdamsvej 3, 2200 Copenhagen N, Denmark
    Diabetologia 48:612-5. 2005
  2. ncbi Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
    Philip J Larsen
    Rheoscience A S, The Panum Insitute, University of Copenhagen, Glerupvej 2, 2610 Rødovre, Denmark
    Regul Pept 128:97-107. 2005
    ....
  3. ncbi Delayed β-cell response and glucose intolerance in young women with Turner syndrome
    Britta E Hjerrild
    Department of Endocrinology and Internal Medicine and Medical Research Laboratories, Aarhus Sygehus NBG, Aarhus University Hospital, Denmark
    BMC Endocr Disord 11:6. 2011
    ..To investigate glucose homeostasis in detail in Turner syndrome (TS), where impaired glucose tolerance (IGT) and type 2 diabetes are frequent...
  4. ncbi Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
    J J Holst
    Department of Medical Physiology, University of Copenhagen, Denmark
    Diabetes 47:1663-70. 1998
    ..Thus, DPP-IV inhibition may be an effective supplement to diet and exercise treatment in attempts to prevent the deterioration of glucose metabolism associated with the Western lifestyle...
  5. ncbi Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
    J J Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen, Denmark
    Diabetologia 49:253-60. 2006
    ..The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006...
  6. ncbi On the physiology of GIP and GLP-1
    J J Holst
    Department of Medical Physiology, University of Copenhagen, 2200 Copenhagen N, Denmark
    Horm Metab Res 36:747-54. 2004
    ..Cardiovascular and neuroprotective actions of GLP-1 have also recently been reported. Regarding GIP, several lines of evidence suggest that GIP, in addition to its incretin effects, may affect lipid metabolism and promote lipid storage...
  7. ncbi The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism
    Jens Juul Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Diabetes 53:S197-204. 2004
    ....
  8. ncbi Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
    Jens Juul Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK 2200 Copenhagen N, Denmark
    Curr Opin Pharmacol 4:589-96. 2004
    ..Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials...
  9. ncbi Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
    Jens Juul Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 287:E199-206. 2004
    ..Because of this, analogs of GLP-1 or GLP-1 receptor activations are currently being developed for diabetes treatment, so far with very promising results...
  10. ncbi Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors
    Jens Juul Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK 2200 Copenhagen N, Denmark
    Adv Exp Med Biol 524:263-79. 2003
    ..Even the effects of GLP-1 effects on the pancreatic islets may be partly neurally mediated and therefore uninfluenced by DPP-IV inhibition...
  11. ncbi Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
    Jens Juul Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, Copenhagen N, Denmark
    Diabetes Metab Res Rev 18:430-41. 2002
    ..Both approaches have shown remarkable efficacy in both experimental and clinical studies. The GLP-1-based therapy of type 2 diabetes, therefore, represents a new and attractive alternative...
  12. ncbi The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno--ileal loop?
    Lene Hansen
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 N, Copenhagen, Denmark
    Regul Pept 110:39-45. 2002
    ..Thus, we find it unlikely that endocrine agents from the duodenum regulate GLP-1 secretion in pigs...
  13. ncbi Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
    Jens Juul Holst
    The Panum Institute, University of Copenhagen, Denmark
    Expert Opin Emerg Drugs 9:155-66. 2004
    ..Orally active DPP-IV inhibitors, suitable for once-daily administration, have demonstrated similar efficacy. Diabetes therapy, based on GLP-1 receptor activation, therefore, appears very promising...
  14. ncbi Incretin hormones--an update
    J J Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Scand J Clin Lab Invest Suppl 234:75-85. 2001
    ..During the last years, therefore, several most promising attempts have been made to develop GLP-1 into a clinically useful therapeutic agent for the treatment of type 2 diabetes...
  15. ncbi On the treatment of diabetes mellitus with glucagon-like peptide-1
    J J Holst
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Denmark
    Ann N Y Acad Sci 865:336-43. 1998
    ..It seems likely that one or more of these approaches could result in a clinically useful development program...
  16. ncbi Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Jens J Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, Copenhagen, Denmark
    BioDrugs 16:175-81. 2002
    ..Therefore, antagonistic analogues of GIP may be speculated to have a role in the pharmaceutical management of obesity...
  17. ncbi Glucagon-like peptide-1, glucose homeostasis and diabetes
    Jens J Holst
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Trends Mol Med 14:161-8. 2008
    ..The pathophysiological basis the clinical use of these therapeutics is reviewed here...
  18. ncbi Glucagon and glucagon-like peptides 1 and 2
    Jens Juul Holst
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, 2200, Copenhagen, Denmark
    Results Probl Cell Differ 50:121-35. 2010
    ..A number of transcription factors have been identified that can at least partly explain the differential cellular expression of the glucagon gene as well as the differential tissue-specific processing of the precursor...
  19. ncbi The physiology of glucagon-like peptide 1
    Jens Juul Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Physiol Rev 87:1409-39. 2007
    ..Decreased secretion of GLP-1 may contribute to the development of obesity, and exaggerated secretion may be responsible for postprandial reactive hypoglycemia...
  20. ncbi Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate
    Jens J Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Scand J Gastroenterol 42:814-20. 2007
    ....
  21. ncbi [Glucagon-like peptide-1--a new hormone and a new drug]
    J J Holst
    Københavns Universitet, Panum Instituttet, Medicinsk Fysiologisk Institut
    Ugeskr Laeger 160:2371-7. 1998
    ....
  22. ncbi The incretin system and its role in type 2 diabetes mellitus
    Jens Juul Holst
    University of Copenhagen, Department of Biomedical Sciences, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Mol Cell Endocrinol 297:127-36. 2009
    ..Orally active DPP-4 inhibitors and the metabolically stable activators, exenatide (Byetta), are now on the market, and numerous clinical studies have shown that both principles are associated with durable antidiabetic activity...
  23. ncbi Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
    M B Toft-Nielsen
    Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, DK-2650 Hvidovre, Denmark
    J Clin Endocrinol Metab 86:3853-60. 2001
    ..Not all patients can be expected to reach normoglycemia...
  24. ncbi Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
    M B Toft-Nielsen
    Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, DK-2650 Hvidovre, Denmark
    J Clin Endocrinol Metab 86:3717-23. 2001
    ..We conclude that the meal-related glucagon-like peptide-1 response in type 2 diabetes is decreased, which may contribute to the decreased incretin effect in type 2 diabetes...
  25. ncbi No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabet Med 18:144-9. 2001
    ..Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients...
  26. ncbi Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Denmark
    Gut 47:370-6. 2000
    ..Ileum resected short bowel patients with a preserved colon show evidence of functional adaptation and have normal gastric emptying...
  27. ncbi Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats
    L Simonsen
    Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 11:884-90. 2009
    ..The present study aimed to evaluate whether long-term administration of exendin-4 to GK rats in the diabetic period would improve their diabetes and how glycaemic control was affected following drug wash-out...
  28. ncbi Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects
    S H Jacobsen
    Department of Endocrinology 541, Hvidovre Hospital, University of Copenhagen, Kettegaard Alle 30, 2650 Hvidovre, Copenhagen, Denmark
    Obes Surg 22:1084-96. 2012
    ..We present a detailed analysis of the early hormone changes after RYGB in response to three different oral test meals designed to provide this information without causing side effects (such as dumping)...
  29. ncbi Evaluation of beta-cell secretory capacity using glucagon-like peptide 1
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Diabetes Care 23:807-12. 2000
    ..Beta-cell secretory capacity is often evaluated with a glucagon test or a meal test. However, glucagon-like peptide 1 (GLP-1) is the most insulinotropic hormone known, and the effect is preserved in type 2 diabetic patients...
  30. ncbi Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabetes 50:609-13. 2001
    ....
  31. ncbi Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Diabetes 47:764-9. 1998
    ..9 40 min x pmol x l(-1); P < 0.05). These results suggest that by reducing GLP-1 degradation, DPP IV inhibition potentiates the insulinotropic effect of GLP-1 and may, therefore, be a viable approach to the management of diabetes...
  32. ncbi PACAP 1-38 as neurotransmitter in the porcine antrum
    K Tornøe
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200, N, Copenhagen, Denmark
    Regul Pept 101:109-21. 2001
    ..Conclusion: PACAP 1-38 may be involved in antral motility and secretion by interacting with cholinergic, SP-ergic, GRP-ergic and/or VIP-ergic neurones, and may also be involved in afferent reflex pathways...
  33. ncbi Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2
    J Thulesen
    Department of Medical Anatomy, University of Copenhagen, The Panum Institute, 2200 N, Copenhagen, Denmark
    Peptides 21:1511-7. 2000
    ....
  34. ncbi Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
    Filip K Knop
    Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 14:500-10. 2012
    ....
  35. ncbi Release of galanin from isolated perfused porcine adrenal glands: role of splanchnic nerves
    J J Holst
    Institute of Medical Physiology C, Panum Institute, Copenhagen, Denmark
    Am J Physiol 261:E31-40. 1991
    ..It is concluded that galanin, coreleased with catecholamines from the adrenal glands, may have endocrine functions but that galanin may also have local regulatory functions in the adrenals...
  36. ncbi Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    Diabetologia 45:1111-9. 2002
    ..Our investigation evaluated "early" (protocol 1) - and "late phase" (protocol 2) insulin and C-peptide responses to GLP-1 and GIP stimulation in patients with Type II diabetes...
  37. ncbi Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects
    K B Hansen
    Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57, DK 2600 Glostrup, Denmark
    J Clin Endocrinol Metab 95:3309-17. 2010
    ..We investigated whether reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet in healthy young males would impair the incretin effect...
  38. ncbi Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy
    O Andersen
    Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark
    HIV Med 6:91-8. 2005
    ....
  39. ncbi Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal--jejunal transposition or small bowel resection
    J Thulesen
    Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Denmark
    Dig Dis Sci 46:379-88. 2001
    ..The adaptive intestinal growth is associated with increased plasma levels of GLP-2, and GLP-2 seems to act in an endocrine as well as a paracrine manner...
  40. ncbi Localisation and neural control of the release of calcitonin gene-related peptide (CGRP) from the isolated perfused porcine ileum
    T N Rasmussen
    Department of Surgical Gastroenterology C, Rigshospitalet and Departments of Medical Physiology and Anatomy B, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Regul Pept 98:137-43. 2001
    ..The stimulatory effect of capsaicin suggests that CGRP is also released from extrinsic sensory neurons...
  41. ncbi Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass
    C Dirksen
    Department of Endocrinology 541, Hvidovre Hospital, University of Copenhagen, Kettegaard Alle 30, 2650 Hvidovre, Denmark
    Diabetologia 55:1890-901. 2012
    ..Later a weight loss induced improvement in peripheral insulin sensitivity follows...
  42. ncbi Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
    K Aaboe
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabetes Obes Metab 12:323-33. 2010
    ....
  43. ncbi Glucose-stimulated prehepatic insulin secretion is associated with circulating alanine, triglyceride, glucagon, lactate and TNF-alpha in patients with HIV-lipodystrophy
    S B Haugaard
    Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Copenhagen, Denmark
    HIV Med 7:163-72. 2006
    ....
  44. ncbi Short-term insulin treatment prevents the diabetogenic action of streptozotocin in rats
    J Thulesen
    University of Copenhagen, Panum Institute, Denmark
    Endocrinology 138:62-8. 1997
    ..We conclude that exogenous insulin suppresses the expression of GLUT2 and insulin in beta-cells, and this may prevent the diabetogenic effect of streptozotocin...
  45. ncbi Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Diabetes 50:1588-97. 2001
    ..Nevertheless, DPP IV inhibition increases the proportion of intact peptide sufficiently to enhance its insulinotropic and antihyperglycemic effects...
  46. ncbi Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis
    C Hedetoft
    Department of Gastroenterology, Glostrup Hospital, Copenhagen, Denmark
    Pancreas 20:25-31. 2000
    ..In conclusion, GLP-1 treatment may be considered in patients with diabetes mellitus secondary to chronic pancreatitis, provided that a certain amount of alpha- and beta-cell secretory capacity is still present...
  47. ncbi Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits
    A P Gjesing
    Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, University of Copenhagen, Universitetsparken 1, DK 2100 Copenhagen, Denmark
    Diabetologia 55:1338-45. 2012
    ....
  48. ncbi Effect of calcitonin gene-related peptide (CGRP) on motility and on the release of substance P, neurokinin A, somatostatin and gastrin in the isolated perfused porcine antrum
    T N Rasmussen
    Department of Surgical Gastroenterology C, Rigshospitalet, University of Copenhagen, Denmark
    Neurogastroenterol Motil 13:353-9. 2001
    ..in addition, pCGRP increases the release of somatostatin but has no effect on gastrin release in the isolated perfused porcine antrum...
  49. ncbi Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
    F K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900, Hellerup, Denmark
    Diabetologia 50:797-805. 2007
    ..We investigated glucagon responses during OGTT and isoglycaemic i.v. glucose infusion, respectively, to further elucidate the mechanisms behind the glucose intolerance in patients with type 2 diabetes...
  50. ncbi Complete sequences of glucagon-like peptide-1 from human and pig small intestine
    C Orskov
    Department of Clinical Chemistry, Rigshospitalet, Copenhagen, Denmark
    J Biol Chem 264:12826-9. 1989
    ..Furthermore, mass spectrometry of the methyl-esterified peptide showed an increase in mass compatible with the presence of alpha-carboxyl amidation. Thus, the gut-derived insulinotrophic hormone GLP-1 is shown to be PG 78-107 amide...
  51. ncbi Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine
    T Buhl
    Institute of Medical Physiology C, Panum Institute, Copenhagen, Denmark
    J Biol Chem 263:8621-4. 1988
    ..By isocratic high pressure liquid chromatography human spacer peptide 2 was indistinguishable from synthetic proglucagon 111-122 amide, suggesting that this is the structure of the naturally occurring human peptide...
  52. ncbi Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1
    S S Torekov
    Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
    Diabetologia 54:2820-31. 2011
    ..The glucagon gene (GCG) encodes several hormones important for energy metabolism: glucagon, oxyntomodulin and glucagon-like peptide (GLP)-1 and -2. Variants in GCG may associate with type 2 diabetes, obesity and/or related metabolic traits...
  53. ncbi Inhibition of human gastric lipase by intraduodenal fat involves glucagon-like peptide-1 and cholecystokinin
    M Wøjdemann
    Department of Surgery, Rigshospitalet, National University Hospital, Copenhagen, Denmark
    Regul Pept 80:101-6. 1999
    ..5 to 15.1 +/- 1.5 pmol/l (P < 0.05) and from 1.2 +/- 0.4 to 3.8 +/- 0.9 pmol/l (P < 0.05). This study reveals a negative effect of fat in the duodenum on gastric lipase secretion. This effect may be mediated by GLP-1 and/or CCK...
  54. ncbi Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal
    J H Henriksen
    Departments of Clinical Physiology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
    Hepatology 29:1818-24. 1999
    ..The hepatosplanchnic bed drained through hepatic veins could not be identified as a source of increased circulating leptin in cirrhosis, but a contribution by the portosystemic collateral flow cannot be excluded...
  55. ncbi Diurnal metabolic profiles after 14 d of an ad libitum high-starch, high-sucrose, or high-fat diet in normal-weight never-obese and postobese women
    A Raben
    Research Department of Human Nutrition, Center for Food Research, The Royal Veterinary and Agricultural University, Frederiksberg, and the Department of Medical Physiology, The Panum Institute, The University of Copenhagen, Denmark
    Am J Clin Nutr 73:177-89. 2001
    ..The influence of the amount and type of carbohydrates in the diet on risk factors for obesity, diabetes, and cardiovascular disease remains unclear...
  56. ncbi Release of PYY from pig intestinal mucosa; luminal and neural regulation
    S P Sheikh
    University Department of Clinical Chemistry, Rigshospitalet, University of Copenhagen, Denmark
    Regul Pept 26:253-66. 1989
    ..It is concluded that the secretion of PYY in the pig ileum may be regulated not only by nutritional luminal factors, but also by postsynaptic parasympathetic nerves...
  57. ncbi Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    J Endocrinol 172:355-62. 2002
    ..Total incretin secretion was reduced by DPP IV inhibition, suggesting the possibility of a feedback mechanism...
  58. ncbi Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
    J de Heer
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200, Copenhagen N, Denmark
    Diabetologia 51:2263-70. 2008
    ..We examined whether the islet hormone somatostatin, which strongly inhibits glucagon secretion, is involved in this divergent behaviour...
  59. ncbi Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis
    F K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Regul Pept 164:144-50. 2010
    ..To examine plasma glucagon responses to oral and intravenous (iv) glucose in patients with chronic pancreatitis (CP) and either normal glucose tolerance (NGT), secondary impaired glucose tolerance (IGT) or secondary diabetes mellitus (DM)...
  60. ncbi Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    K B Hansen
    Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej, Copenhagen, Denmark
    Int J Clin Pract 63:1154-60. 2009
    ..In this review, the available data on the two drugs are presented and discussed...
  61. ncbi Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility
    Takashi Miki
    Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    Diabetes 54:1056-63. 2005
    ..Although both GIP and GLP-1 increase the intracellular cAMP concentration and potentiate insulin secretion, these results demonstrate that the GLP-1 and GIP signaling pathways involve the K(ATP) channel differently...
  62. ncbi Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes
    Mette Zander
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetes Care 27:1910-4. 2004
    ..To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes...
  63. ncbi Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
    Yan ling He
    DMSc, Exploratory Development, Novartis Institutes of Biomedical Research Inc, 400 Technology Square, Building 605, Rm 811, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 47:633-41. 2007
    ..Unlike findings during mixed-meal challenges, vildagliptin increases plasma insulin levels during oral glucose tolerance tests in patients with type 2 diabetes mellitus...
  64. ncbi Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
    A Plamboeck
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetologia 48:1882-90. 2005
    ..Dipeptidyl peptidase IV (DPP-IV) is established as the primary inactivating enzyme, but the roles of other enzymes remain unclear...
  65. ncbi Glucagon antagonism as a potential therapeutic target in type 2 diabetes
    J I Bagger
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Diabetes Obes Metab 13:965-71. 2011
    ..This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality...
  66. ncbi Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects
    Anders H Frid
    Clinic of Endocrinology, University Hospital MAS, Malm, Sweden
    Am J Clin Nutr 82:69-75. 2005
    ....
  67. ncbi GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat
    Ayhan Bozkurt
    Department of Physiology, Marmara University, Istanbul, Turkey
    Regul Pept 107:129-35. 2002
    ..In the fed state, GLP-1 and GLP-2 seem to display counter-balancing effects on motility of the small intestine...
  68. ncbi Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling
    J Gromada
    Department of Islet Cell Physiology, Novo Nordisk A S, University of Copenhagen, Denmark
    Diabetes 47:57-65. 1998
    ..The present data suggest that the strong insulinotropic action of GLP-1(7-36) amide and GIP in humans results from its interaction with several proximal as well as distal important regulatory steps in the stimulus-secretion coupling...
  69. ncbi Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable
    C Orskov
    Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
    Diabetes 42:658-61. 1993
    ..6 +/- 2.4 vs. 12.2 +/- 1.0 pmol/kg x min). In conclusion, COOH-terminal amidation is neither important for the metabolism of GLP-1 nor for its effects on the endocrine pancreas...
  70. ncbi Galanin and galanin extended at the N-terminus with seven and nine amino acids are produced in and secreted from the porcine adrenal medulla in almost equal amounts
    M Bersani
    Department of Medical Physiology C, Panum Institute, University of Copenhagen, Denmark
    Endocrinology 129:2693-8. 1991
    ..The processing of preprogalanin in porcine adrenals thus includes the formation and release of galanin, preprogalanin-(24-61), and preprogalanin-(26-61). The signal peptidase cleaves the preprogalanin at either Gly23 or Gly25...
  71. ncbi Prosomatostatin 1-64 is a major product of somatostatin gene expression in pancreas and gut
    M Bersani
    Institute of Medical Physiology C, Panum Institute, University of Copenhagen, Denmark
    J Biol Chem 264:10633-6. 1989
    ..The eventual hormonal role of pro-SS 1-64 may now be evaluated...
  72. ncbi Role of the vasoactive intestinal peptide in a neuroendocrine regulation of the adrenal cortex
    M Ehrhart-Bornstein
    Institute for Medical Physiology C, University of Copenhagen, Denmark
    Neuroendocrinology 54:623-8. 1991
    ..In this regulatory pathway, the VIP-ergic innervation of the adrenal cortex may be a potent stimulatory element...
  73. ncbi Increased intensity of a single exercise bout stimulates subsequent fat intake
    B Klausen
    Research Department of Human Nutrition, The Royal Veterinary and Agricultural University, Frederiksberg C, Copenhagen, Denmark
    Int J Obes Relat Metab Disord 23:1282-7. 1999
    ..How this change in lifestyle affects the selection of dietary intakes is presently unknown...
  74. ncbi Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight
    Jakob Hagen Schou
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    J Clin Endocrinol Metab 90:4912-9. 2005
    ..Low birth weight (LBW) is associated with increased risk of type 2 diabetes mellitus. An impaired incretin effect was reported previously in type 2 diabetic patients...
  75. ncbi Cholecystokinin inhibits gastrin secretion independently of paracrine somatostatin secretion in the pig
    P T Schmidt
    Dept. of Medical Physiology, Panum Institute, Copenhagen, Denmark
    Scand J Gastroenterol 39:217-21. 2004
    ..CONCLUSION: CCK inhibits gastrin secretion independently of paracrine somatostatin secretion...
  76. ncbi Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
    Mette Zander
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Lancet 359:824-30. 2002
    ..Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this peptide hormone in a 6-week pilot study...
  77. ncbi Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
    Thomas Nystrom
    Dept of Internal Medicine, Stockholm South Hospital, Karolinska Institute, Stockholm SE 118 83, Sweden
    Am J Physiol Endocrinol Metab 287:E1209-15. 2004
    ..This beneficial vascular effect of GLP-1 adds yet another salutary property of the peptide useful in diabetes treatment...
  78. ncbi Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    J Clin Endocrinol Metab 85:3575-81. 2000
    ..05). We conclude that dipeptidyl peptidase IV is important in GIP metabolism in humans in vivo, and that an N-terminally directed assay is required for determination of plasma concentrations of biologically active GIP...
  79. ncbi KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
    Kasper Aaboe
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, Hellerup DK 2900, Denmark
    J Clin Endocrinol Metab 94:603-8. 2009
    ..With this study we therefore aimed at clarifying the role of K(ATP) channel malfunction in the impaired function of GIP...
  80. ncbi Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
    Dennis B Henriksen
    Nordic Bioscience, Herlev Hovedgade 207, DK 2730 Herlev, Denmark
    Bone 34:140-7. 2004
    ..07) by the treatment, suggestive of a stimulative effect on bone formation. An area under the curve (AUC0-10 h) analysis for s-CTX after GLP-2 injection confirmed the dose-related decrease as compared to placebo (P < 0.05)...
  81. ncbi Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation
    T Hansen
    Steno Diabetes Center and Hagendorn Research Institute, Copenhagen, Denmark
    Diabetes 46:726-30. 1997
    ....
  82. ncbi Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
    L Simonsen
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetologia 49:706-12. 2006
    ..The data suggest that in the anaesthetised pig, extraction occurs only in the kidney and can be fully accounted for by glomerular filtration...
  83. ncbi GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
    Kristine Mortensen
    Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Blegdamsvej 3 C, Copenhagen DK-2200, Denmark
    Regul Pept 114:189-96. 2003
    ..CONCLUSIONS: Our results provide a morphological basis to suggest simultaneous, rather than sequential, secretion of these hormones by postprandial luminal stimulation...
  84. ncbi Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells
    Steen B Haugaard
    Department of Infectious Diseases, Hvidovre University Hospital, DK 2650, Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 287:E677-85. 2004
    ....
  85. ncbi Functional and immunohistochemical evaluation of porcine neonatal islet-like cell clusters
    T B Nielsen
    Department of Medical Endocrinology, Odense University Hospital, Denmark
    Cell Transplant 12:13-25. 2003
    ..There was a potential for expansion of the beta-cell mass of NICCs in vitro as well as in vivo where NICCs eventually may normalize blood glucose of diabetic mice...
  86. ncbi Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice
    Heidi Sørensen
    Diabetes Research Unit, Novo Nordisk Park, 2760 Måløv, Denmark
    Diabetes 55:2843-8. 2006
    ..In conclusion, acute and subchronic neutralization of endogenous glucagon improves glycemic control, thus supporting the contention that glucagon antagonism may represent a beneficial treatment of diabetes...
  87. ncbi Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease
    Thierry Piche
    , Nantes, France
    Gastroenterology 124:894-902. 2003
    ..Although different mechanisms are likely to be involved, excess release of GLP-1 may account, at least in part, for these effects...
  88. ncbi Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs
    Carl Frederik Nagell
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Scand J Gastroenterol 41:667-72. 2006
    ....
  89. ncbi Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight
    Christine B Jensen
    Department of Endocrinology and Clinical Research Unit, Hvidovre University Hospital, Hvidovre, Denmark
    Diabetes 51:1271-80. 2002
    ..We propose that reduced insulin-stimulated glycolysis precedes overt insulin resistance in LBW men. A lower insulin secretion may contribute to impaired glucose tolerance and ultimately lead to diabetes...
  90. ncbi Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice
    J Thulesen
    Department of Medical Anatomy, Section B, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Gut 53:1145-50. 2004
    ..However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine...
  91. ncbi Human galanin: primary structure and identification of two molecular forms
    M Bersani
    Panum Institute, University of Copenhagen, Denmark
    FEBS Lett 283:189-94. 1991
    ..Thus, human galanin includes two peptides of 19 and 30 amino acids that share the sequence of the N-terminal 15 residues with other mammalian galanins, but exhibit characteristic differences in the remaining part of the molecules...
  92. ncbi Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects
    Birgitte Sloth
    Department of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, 30 Rolighedsvej, DK 1958 Frederiksberg C, Denmark
    Am J Physiol Endocrinol Metab 292:E1062-8. 2007
    ..Furthermore, high-dose [corrected] PYY(3-36) (0.8 [corrected] pmol x kg(-1) x min(-1)) produced decreased [corrected] EI and increased postprandial [corrected] glucose concentrations and tendency to reduced EE [corrected]..
  93. ncbi Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells
    Steen B Haugaard
    Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark
    Eur J Endocrinol 152:103-12. 2005
    ..Aiming to provide a detailed description of the metabolic adverse effects of HIV-lipodystrophy, we investigated several aspects of glucose metabolism, lipid metabolism and beta-cell function in lipodystrophic HIV-infected patients...
  94. ncbi Inhibition of gastric inhibitory polypeptide signaling prevents obesity
    Kazumasa Miyawaki
    Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Nat Med 8:738-42. 2002
    ..Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs...
  95. ncbi Acute effects of ghrelin administration on glucose and lipid metabolism
    Esben Thyssen Vestergaard
    Medical Department M Endocrinology and Diabetes, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Endocrinol Metab 93:438-44. 2008
    ..Ghrelin infusion increases plasma glucose and nonesterified fatty acids, but it is uncertain whether this is secondary to the concomitant release of GH...
  96. ncbi Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding
    Judith Korner
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Surg Obes Relat Dis 3:597-601. 2007
    ....
  97. ncbi Young, low-birth-weight men are not more susceptible to the diabetogenic effects of a prolonged free fatty acid exposure than matched controls
    Christine B Jensen
    Steno Diabetes Center, DK 2820 Gentofte, Denmark
    Metabolism 54:1398-406. 2005
    ..We reproduced our previous finding of lower insulin-stimulated glycolysis in this population...
  98. ncbi The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Denmark
    Regul Pept 137:168-72. 2006
    ..Differences in elimination of GIP and its primary metabolite, therefore, do not seem to contribute to the defective insulinotropic effect of GIP in type 2 diabetes...
  99. ncbi Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males
    Birgitte Sloth
    Dept of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, Univ of Copenhagen, 30 Rolighedsvej, DK 1958 Frederiksberg, Denmark
    Am J Physiol Endocrinol Metab 293:E604-9. 2007
    ..PYY(1-36) is unlikely to be important in regulating energy intake. The PYY(3-36) administrations caused a non-dose-dependent mobilization of FFA, likely through a direct effect...
  100. ncbi Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus
    Katarzyna Cypryk
    Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Polish Mother s Memorial Hospital Research Institute, Lodz, Poland
    Gynecol Endocrinol 23:58-62. 2007
    ..The aim of study was to evaluate whether an impaired secretion of glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) could play a role in the development of carbohydrate disorders during pregnancy...
  101. ncbi Elevated circulating leptin levels in arterial hypertension: relationship to arteriovenous overflow and extraction of leptin
    J H Henriksen
    Department of Clinical Physiology, Hvidovre Hospital, University of Copenhagen, DK 2650 Hvidovre, Denmark
    Clin Sci (Lond) 99:527-34. 2000
    ..Leptin kinetics in arterial hypertension require further investigation...